Journal article
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
SHI Ou, EL Kwak, C Siwak-Tapp, J Dy, K Bergethon, JW Clark, DR Camidge, BJ Solomon, RG Maki, YJ Bang, DW Kim, J Christensen, W Tan, KD Wilner, R Salgia, AJ Iafrate
Journal of Thoracic Oncology | ELSEVIER SCIENCE INC | Published : 2011
Abstract
Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor. Copyright © 2011 by the International Association for the Study of Lung Cancer.
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
Supported by (A8081001, ClinicalTrials.gov identifier NCT00585195) Pfizer, Inc. Ravi Salgia, MD, PhD, is supported by grant 5RO1CA125541-05.